Cytori Therapeutics, Inc. (CYTX) Reports Larger Q3 Loss

Cytori Therapeutics, Inc. (NASDAQ: CYTX) reported Q1 EPS of ($0.23), $0.08 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $3.21 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance